BICARA THERAPEUTICS INC
BCAX
Health Care
1
exclusion reason
1 theme
BICARA THERAPEUTICS INC is screened out under 1 exclusion reason spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Bicara Therapeutics Inc. is a clinical-stage biotechnology company developing bifunctional antibody therapies for cancer treatment. As part of its pharmaceutical product development and regulatory compliance process, the company conducts extensive preclinical testing, which includes animal studies. Its 2024 annual report references the completion of nonclinical animal tests as a standard component of its research pipeline. The company’s therapies, such as those targeting head and neck squamous cell carcinoma, are evaluated in preclinical models, including murine studies, to assess efficacy and safety before advancing to human clinical trials. This reliance on animal testing is integral to its business model as a drug developer seeking FDA approval.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.